An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers
Latest Information Update: 16 Aug 2022
At a glance
- Drugs JW 0101+C 2101 (Primary) ; Pitavastatin/valsartan (Primary)
- Indications Hyperlipidaemia; Hypertension
- Focus Pharmacokinetics
- Sponsors JW Pharmaceutical
Most Recent Events
- 06 May 2022 New trial record